Pharmacokinetic and pharmacodynamic comparison of once-daily efavirenz (400 mg vs. 600 mg) in treatment-naïve HIV-infected patients: results of the ENCORE1 Study

L. Dickinson*, J. Amin, L. Else, M. Boffito, D. Egan, A. Owen, S. Khoo, D. Back, C. Orrell, A. Clarke, M. Losso, P. Phanuphak, D. Carey, D. A. Cooper, S. Emery, R. Puls

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

62 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Pharmacokinetic and pharmacodynamic comparison of once-daily efavirenz (400 mg vs. 600 mg) in treatment-naïve HIV-infected patients: results of the ENCORE1 Study'. Together they form a unique fingerprint.

Medicine & Life Sciences